$PRME
Prime Medicine Inc Stock $prme

$prme Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000162828022029889 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.625M	$6.608M	$3.027M
YoY Change	33.92%	118.3%
% of Gross Profit
Research & Development	$29.06M	$25.05M	$7.400M
YoY Change	-45.05%	238.47%
% of Gross Profit
Depreciation & Amortization	$870.0K	$631.0K	$167.0K
YoY Change	279.91%	277.84%	735.0%
% of Gross Profit
Operating Expenses	$38.69M	$31.66M	$10.43M
YoY Change	-35.6%	203.59%
Operating Profit		-$31.66M	-$10.43M
YoY Change		203.59%
Interest Expense	-$1.709M	$1.789M	-$8.354M
YoY Change	16.58%	-121.41%
% of Operating Profit
Other Income/Expense, Net	$926.0K	$728.0K	-$1.000K
YoY Change	7616.67%	-72900.0%
Pretax Income	-$39.47M	-$29.14M	-$18.78M
YoY Change	-35.85%	55.14%
Income Tax	-$186.0K	$212.0K	-$2.370M
% Of Pretax Income
Net Earnings	-$40.60M	-$35.71M	-$22.78M
YoY Change	-41.4%	56.8%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.61	-$1.52
Diluted Earnings Per Share	-$0.38	-$0.38	-$0.24
COMMON SHARES
Basic Shares Outstanding	97.21M shares	22.23M shares	14.97M shares
Diluted Shares Outstanding		22.23M shares	14.97M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$286.1M	$146.7M	$299.9M
YoY Change	6.11%	-51.1%
Cash & Equivalents	$187.6M	$47.95M	$200.7M
Short-Term Investments	$98.47M	$98.72M	$99.26M
Other Short-Term Assets	$2.697M	$2.180M	$485.0K
YoY Change	181.23%	349.48%
Inventory
Prepaid Expenses	$2.451M
Receivables
Other Receivables
Total Short-Term Assets	$296.6M	$148.8M	$300.4M
YoY Change	9.62%	-50.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.01M	$47.31M	$13.99M
YoY Change	21.25%	238.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.646M	$19.11M	$794.0K
YoY Change	-89.45%	2306.68%
Total Long-Term Assets	$63.70M	$66.42M	$14.78M
YoY Change	103.65%	349.27%
TOTAL ASSETS
Total Short-Term Assets	$296.6M	$148.8M	$300.4M
Total Long-Term Assets	$63.70M	$66.42M	$14.78M
Total Assets	$360.3M	$215.3M	$315.2M
YoY Change	19.37%	-31.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.332M	$4.111M	$1.356M
YoY Change	201.88%	203.17%
Accrued Expenses	$10.69M	$16.76M	$8.176M
YoY Change	-75.45%	104.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.71M	$22.22M	$9.544M
YoY Change	-53.93%	132.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$17.05M	$19.86M	$4.267M
YoY Change	455.41%	365.46%
Total Long-Term Liabilities	$17.05M	$19.86M	$4.267M
YoY Change	455.41%	365.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.71M	$22.22M	$9.544M
Total Long-Term Liabilities	$17.05M	$19.86M	$4.267M
Total Liabilities	$44.04M	$42.56M	$13.81M
YoY Change	-29.3%	208.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$293.2M	-$253.9M
YoY Change	71.09%
Common Stock	$2.000K	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$316.3M	$172.7M	$301.4M
YoY Change
Total Liabilities & Shareholders Equity	$360.3M	$215.3M	$315.2M
YoY Change	19.37%	-31.7%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$40.60M	-$35.71M	-$22.78M
YoY Change	-41.4%	56.8%
Depreciation, Depletion And Amortization	$870.0K	$631.0K	$167.0K
YoY Change	279.91%	277.84%	735.0%
Cash From Operating Activities	-$30.71M	-$30.10M	-$9.606M
YoY Change	132.9%	213.33%	213.92%
INVESTING ACTIVITIES
Capital Expenditures	$4.814M	$4.791M	$1.824M
YoY Change	1160.21%	162.66%	436.47%
Acquisitions
YoY Change
Other Investing Activities	-$8.873M	-$8.720M	-$5.812M
YoY Change	-170.78%	50.03%	1514.44%
Cash From Investing Activities	-$13.69M	-$13.51M	-$7.636M
YoY Change	-212.61%	76.94%	975.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$63.00K	-$1.000K
YoY Change		-6400.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	184.1M	-683.0K	-1.000K
YoY Change	-17049.63%	68200.0%	-95.0%
NET CHANGE
Cash From Operating Activities	-30.71M	-30.10M	-9.606M
Cash From Investing Activities	-13.69M	-13.51M	-7.636M
Cash From Financing Activities	184.1M	-683.0K	-1.000K
Net Change In Cash	139.7M	-44.29M	-17.24M
YoY Change	-6691.46%	156.87%	354.96%
FREE CASH FLOW
Cash From Operating Activities	-$30.71M	-$30.10M	-$9.606M
Capital Expenditures	$4.814M	$4.791M	$1.824M
Free Cash Flow	-$35.53M	-$34.89M	-$11.43M
YoY Change	161.82%	205.24%	236.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001894562
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-04321
	dei	Entity Registrant Name EntityRegistrantName	Prime Medicine, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3097762
	dei	Entity Address Address Line1 EntityAddressAddressLine1	21 Erie Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
	dei	City Area Code CityAreaCode	(617)
	dei	Local Phone Number LocalPhoneNumber	564-0013
	dei	Security12b Title Security12bTitle	Common stock, par value $0.00001 per share
	dei	Trading Symbol TradingSymbol	PRME
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	97208342	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47947000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	185420000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	89175000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	68238000	usd
CY2022Q3	prme	Short Term Investments Related Parties ShortTermInvestmentsRelatedParties	9543000	usd
CY2021Q4	prme	Short Term Investments Related Parties ShortTermInvestmentsRelatedParties	15962000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2180000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	959000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	148845000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	270579000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14967000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4932000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32344000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10746000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13496000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13125000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5613000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2474000	usd
CY2022Q3	us-gaap	Assets Assets	215265000	usd
CY2021Q4	us-gaap	Assets Assets	301856000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4111000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1435000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6530000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	37192000	usd
CY2022Q3	prme	Related Party Forward Contract Liability Current RelatedPartyForwardContractLiabilityCurrent	0	usd
CY2021Q4	prme	Related Party Forward Contract Liability Current RelatedPartyForwardContractLiabilityCurrent	12020000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11577000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7336000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	22218000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	57983000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19862000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3070000	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	481000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1243000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	42561000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	62296000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	293258790	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	293258790	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33559912	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33559912	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32413860	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32413860	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31272000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	15163000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-454000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-27000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-253914000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171376000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-223096000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-156240000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	215265000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	301856000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25047000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7400000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57664000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17661000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6608000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3027000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20194000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6737000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	31655000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	10427000	usd
	us-gaap	Operating Expenses OperatingExpenses	77858000	usd
	us-gaap	Operating Expenses OperatingExpenses	24398000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-31655000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10427000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-77858000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24398000	usd
CY2022Q3	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	0	usd
CY2021Q3	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	0	usd
	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	0	usd
	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	-74319000	usd
CY2022Q3	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	0	usd
CY2021Q3	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	0	usd
	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	0	usd
	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	-6681000	usd
CY2022Q3	prme	Change In Fair Value Of Related Party Short Term Investment ChangeInFairValueOfRelatedPartyShortTermInvestment	1789000	usd
CY2021Q3	prme	Change In Fair Value Of Related Party Short Term Investment ChangeInFairValueOfRelatedPartyShortTermInvestment	-8354000	usd
	prme	Change In Fair Value Of Related Party Short Term Investment ChangeInFairValueOfRelatedPartyShortTermInvestment	-6419000	usd
	prme	Change In Fair Value Of Related Party Short Term Investment ChangeInFairValueOfRelatedPartyShortTermInvestment	1075000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	728000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	977000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2517000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8355000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5442000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-79925000	usd
CY2022Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-29138000	usd
CY2021Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-18782000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-83300000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-104323000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	212000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2370000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-762000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1867000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-29350000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-16412000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-82538000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-102456000	usd
CY2022Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2021Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1468000	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6362000	usd
CY2021Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6363000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	18879000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	10922000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-35712000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35712000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-22775000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22775000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-101417000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-101417000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-114846000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-114846000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.61
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.61
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.52
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.52
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.74
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.74
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22226301	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22226301	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14965186	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14965186	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20665225	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20665225	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11795738	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11795738	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-29350000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-16412000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-82538000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-102456000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-304000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	25000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-427000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-9000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-304000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	25000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-427000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29654000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16387000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-82965000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102465000	usd
CY2022Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	usd
CY2021Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	usd
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	usd
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	429000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-156240000	usd
CY2022Q1	prme	Additional Paid In Capital Reclassification Of Related Party Forward Contract Value AdditionalPaidInCapitalReclassificationOfRelatedPartyForwardContractValue	12020000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1123000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-23840000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-166942000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1345000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-29348000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-118000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-195063000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	204000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	339000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-16412000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	25000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1417000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-29350000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-304000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-223096000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2338000	usd
CY2021Q1	prme	Adjustments To Additional Paid In Capital Temporary Equity Accretion To Redemption Value AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue	1194000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	206000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-86660000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-85310000	usd
CY2021Q2	prme	Adjustments To Additional Paid In Capital Temporary Equity Stock Issued During Period Value New Issues AdjustmentsToAdditionalPaidInCapitalTemporaryEquityStockIssuedDuringPeriodValueNewIssues	998000	usd
CY2021Q2	prme	Adjustments To Additional Paid In Capital Temporary Equity Accretion To Redemption Value AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue	274000	usd
CY2021Q2	prme	Stock Issued During Period Settlement Of Anti Dilution Obligation Value StockIssuedDuringPeriodSettlementOfAntiDilutionObligationValue	7536000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	94000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	616000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-34000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-78370000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-94418000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-82538000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-102456000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1354000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	339000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-100000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3885000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	639000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	6992000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2910000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-762000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1867000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	0	usd
	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	-74319000	usd
	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	0	usd
	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	-6681000	usd
	prme	Change In Fair Value Of Related Party Short Term Investment ChangeInFairValueOfRelatedPartyShortTermInvestment	-6419000	usd
	prme	Change In Fair Value Of Related Party Short Term Investment ChangeInFairValueOfRelatedPartyShortTermInvestment	1075000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1080000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	642000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2027000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1105000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-29961000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1896000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-7558000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2744000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-101114000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20895000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11281000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3768000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	89464000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	81841000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	68000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	usd
	prme	Payments For Security Deposits PaymentsForSecurityDeposits	664000	usd
	prme	Payments For Security Deposits PaymentsForSecurityDeposits	171000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-33409000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-85780000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2642000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	63000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2579000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	270364000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-137102000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	163689000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198545000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36975000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61443000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200664000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	28590000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10103000	usd
	prme	Settlement Of Anti Dilution Rights SettlementOfAntiDilutionRights	0	usd
	prme	Settlement Of Anti Dilution Rights SettlementOfAntiDilutionRights	7536000	usd
	prme	Settlement Of Related Party Forward Contract SettlementOfRelatedPartyForwardContract	12020000	usd
	prme	Settlement Of Related Party Forward Contract SettlementOfRelatedPartyForwardContract	0	usd
	prme	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	239000	usd
	prme	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	870000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	0	usd
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1468000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	454000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	9000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47947000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	200664000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	13496000	usd
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61443000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200664000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-253900000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	146700000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include, but are not limited to, revenue recognition, the valuation of the Company’s common stock and stock-based awards, the valuation of preferred stock tranche right liability, the valuation of the anti-dilution obligation and the valuation of the related party forward contract liability. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ materially from those estimates or assumptions.</span></div>
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	28800000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	49500000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13500000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13100000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	9543000	usd
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	127537000	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	15962000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	133650000	usd
CY2021Q4	prme	Related Party Forward Contract Liability Fair Value Disclosure RelatedPartyForwardContractLiabilityFairValueDisclosure	12020000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	12020000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Cost EquitySecuritiesFvNiCost	5486000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	4057000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	0	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	9543000	usd
CY2022Q3	prme	Debt And Equity Securities Amortized Cost DebtAndEquitySecuritiesAmortizedCost	95115000	usd
CY2022Q3	prme	Debt And Equity Securities Unrealized Gains DebtAndEquitySecuritiesUnrealizedGains	4057000	usd
CY2022Q3	prme	Debt And Equity Securities Unrealized Loss DebtAndEquitySecuritiesUnrealizedLoss	454000	usd
CY2022Q3	prme	Debt And Equity Securities DebtAndEquitySecurities	98718000	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni Cost EquitySecuritiesFvNiCost	5486000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	10476000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	0	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	15962000	usd
CY2021Q4	prme	Debt And Equity Securities Amortized Cost DebtAndEquitySecuritiesAmortizedCost	73751000	usd
CY2021Q4	prme	Debt And Equity Securities Unrealized Gains DebtAndEquitySecuritiesUnrealizedGains	10476000	usd
CY2021Q4	prme	Debt And Equity Securities Unrealized Loss DebtAndEquitySecuritiesUnrealizedLoss	27000	usd
CY2021Q4	prme	Debt And Equity Securities DebtAndEquitySecurities	84200000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	89175000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	68238000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	89175000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	68238000	usd
CY2021	prme	Anti Dilution Obligation Achievement Threshold AntiDilutionObligationAchievementThreshold	100000000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16928000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5543000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1961000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	611000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14967000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4932000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1400000	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	usd
CY2022Q3	prme	Accrued License Fee Current AccruedLicenseFeeCurrent	0	usd
CY2021Q4	prme	Accrued License Fee Current AccruedLicenseFeeCurrent	30000000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4111000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2364000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1070000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3830000	usd
CY2022Q3	prme	Accrued Lab Related Supplies And Services Current AccruedLabRelatedSuppliesAndServicesCurrent	1167000	usd
CY2021Q4	prme	Accrued Lab Related Supplies And Services Current AccruedLabRelatedSuppliesAndServicesCurrent	719000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	182000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	279000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6530000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	37192000	usd
CY2022Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	161420799	shares
CY2022Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	161420799	shares
CY2022Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	161420799	shares
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	395800000	usd
CY2022Q3	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	354693000	usd
CY2022Q3	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	51923758	shares
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	161420799	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	161420799	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	161420799	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	395800000	usd
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	335814000	usd
CY2021Q4	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	51923764	shares
	prme	Convertible Preferred Stock Automatic Conversion Public Offering Amount Threshold ConvertiblePreferredStockAutomaticConversionPublicOfferingAmountThreshold	50000000	usd
CY2021	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0	usd
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0	usd
CY2022Q3	prme	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	57287852	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3002803	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.96
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1160074	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.40
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	55687	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.67
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	135633	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.66
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3971557	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.24
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	536064	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.71
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3971557	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.24
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1417000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	339000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3885000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	639000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P5Y
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2415000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12610000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13035000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3510000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1683000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	567000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	33820000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2381000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	31439000	usd
CY2022Q2	prme	Operating Lease Participation Rights Agreement Amount OperatingLeaseParticipationRightsAgreementAmount	2000000	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	usd
CY2022Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	usd
CY2022Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	300000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-29350000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-16412000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-82538000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-102456000	usd
CY2022Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2021Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1468000	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6362000	usd
CY2021Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6363000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	18879000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	10922000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-35712000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35712000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-22775000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22775000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-101417000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-101417000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-114846000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-114846000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22226301	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22226301	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14965186	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14965186	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20665225	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20665225	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11795738	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11795738	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.61
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.61
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.52
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.52
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.74
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.74
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	66493041	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	69985777	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	293258790	shares

Files In Submission

Name	View Source	Status
0001628280-22-029889-index-headers.html	Edgar Link	pending
0001628280-22-029889-index.html	Edgar Link	pending
0001628280-22-029889.txt	Edgar Link	pending
0001628280-22-029889-xbrl.zip	Edgar Link	pending
ex311.htm	Edgar Link	pending
ex312.htm	Edgar Link	pending
ex321.htm	Edgar Link	pending
ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prme-20220930.htm	Edgar Link	pending
prme-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
prme-20220930_cal.xml	Edgar Link	unprocessable
prme-20220930_def.xml	Edgar Link	unprocessable
prme-20220930_lab.xml	Edgar Link	unprocessable
prme-20220930_pre.xml	Edgar Link	unprocessable
prme-20220930_htm.xml	Edgar Link	completed
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRME
Prime Medicine Inc Stock $prme

2022 Q4 Form 10-Q Financial Statement

#000162828022029889 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRME Prime Medicine Inc Stock $prme

2022 Q4 Form 10-Q Financial Statement

#000162828022029889 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRME
Prime Medicine Inc Stock $prme